Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IQVIA HoldingsLTS:0JDM +0.89%88 3-Year Share Buyback Ratio is 3.00 as of Jun. 2026, which is 131% above its 10-year median of 1.30. GuruFocus rates LTS:0JDM with a GF Score™ of 88/100 and a GF Value™ of $247.48 (Fairly Valued). The stock has 8 warning signs investors should review. Among 172 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 97.67% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. IQVIA Holdings's current 3-Year Share Buyback Ratio was 3.00%.
The historical rank and industry rank for IQVIA Holdings's 3-Year Share Buyback Ratio or its related term are showing as below:
LTS:0JDM'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -22 Med: 1.3 Max: 6.5
Current: 3
During the past 13 years, IQVIA Holdings's highest 3-Year Share Buyback Ratio was 6.50%. The lowest was -22.00%. And the median was 1.30%.
LTS:0JDM's 3-Year Share Buyback Ratio is ranked better than 97.67% of 172
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.6
vs LTS:0JDM: 3.00
IQVIA Holdings (LTS:0JDM) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
IQVIA Holdings 3-Year Share Buyback Ratio Related Terms
LTS:0JDM vs WAT, NTRA, A: 3-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings 3-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's 3-Year Share Buyback Ratio falls into.
IQVIA Holdings 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 3.00 mean?
IQVIA Holdings (LTS:0JDM) has a 3-Year Share Buyback Ratio of 3.00 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for IQVIA Holdings and its competitors. This is 131% above median its historical median of 1.30. According to the industry distribution chart, IQVIA Holdings ranks #4 out of 172 companies in the Medical Diagnostics & Research industry, placing it in the top 2.3%.
Is IQVIA Holdings' 3-Year Share Buyback Ratio too high?
IQVIA Holdings' current 3-Year Share Buyback Ratio of 3.00 is 131% above median its 10-year median of 1.30. Based on the distribution chart, IQVIA Holdings ranks #4 out of 172 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IQVIA Holdings has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' 3-Year Share Buyback Ratio compare to WAT and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #4 out of 172 companies for 3-Year Share Buyback Ratio. This places IQVIA Holdings in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 3-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for IQVIA Holdings and its competitors. IQVIA Holdings's current 3-Year Share Buyback Ratio is 3.00, which is 131% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Fairly Valued. The stock's GF Value™ is $247.48, compared to a current price of $261.57 — trading 5.7% above its estimated fair value. The current 3-Year Share Buyback Ratio is 3.00, which is 131% above median its 10-year median of 1.30. IQVIA Holdings' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current 3-Year Share Buyback Ratio is 3.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be overvalued.
The current stock price of $261.57 is trading 5.7% above its estimated GF Value™ of $247.48.
GuruFocus considers IQVIA Holdings to be Fairly Valued.
Key valuation signals for LTS:0JDM:
3-Year Share Buyback Ratio: 3.00 (131% above median its 10-year median of 1.30)
GF Value™: $247.48 vs. price of $261.57 (5.7% above fair value)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
88GF Score
Get the complete analysis for LTS:0JDM
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
